IDH2, isocitrate dehydrogenase (NADP(+)) 2, 3418

N. diseases: 380; N. variants: 15
Disease: Childhood Glioblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE <b>Abbreviations</b>: CGGA: Chinese Glioma Genome Atlas; TCGA: The Cancer Genome Atlas; TAMs: Tumor associated macrophages; IDH: isocitrate dehydrogenase; GBM: glioblastoma. 31143523 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE <b>Conclusion:</b> High radiation doses to ipsilateral NSC and contralateral SVZ could have a negative impact on overall survival in IDH-wild-type glioblastoma population. 30338243 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 AlteredExpression disease BEFREE IDH activity was the main provider of NADPH in human normal brain and glioblastoma, but its role was modest in NADPH production in rodent brain and other tissues. 21527585 2011
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. 26158269 2015
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 PosttranslationalModification disease BEFREE IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. 26503470 2015
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 PosttranslationalModification disease BEFREE Addition of 2-HG to glioblastoma cultures recapitulates the effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and reduces ATP levels in glioblastoma cells. 29057925 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE After chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM. 29982845 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE All patients were diagnosed with IDH-wild type glioblastoma according to pathological criteria. 29212499 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. 25427834 2015
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE Based on the new histomolecular classification, diagnoses included anaplastic oligodendroglioma IDH mutant and 1p/19q-codeleted (32.5 %), anaplastic astrocytoma IDH mutant (IDH (mut)) (11.0 %), anaplastic astrocytoma IDH wild type (IDH (wt)) (5.3 %), glioblastoma IDH (mut) (17.1 %), and glioblastoma IDH (wt) (33.2 %). 27573687 2016
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples. 20171178 2010
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>. 29921698 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. 25150284 2014
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment. 29920451 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma. 30991024 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE From Jan 2009 to Dec 2016, 161 patients with newly diagnosed IDH-wild type GB were treated with surgery and adjuvant concurrent chemoradiotherapy with the Stupp's regimen, and then genomic research proceeded with their surgical specimens. 30773189 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma. 29720725 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma. 29617848 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. 28401334 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma multiforme (pGBMs) were analyzed for BRAF V600E, IDH1, IDH2, and TP53 mutations. 24057326 2013
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 AlteredExpression disease BEFREE In low-grade glioma (LGG) and glioblastoma cohorts of TCGA, significantly higher PD-L1 gene expression levels were evident in IDH-wt compared with IDH-mut samples (LGG: N = 516; P = 1.933e-11, GBM: N = 161; P < 0.009). 28531337 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE In spite of a recent surge in elucidating the tumorigenic activity of IDH mutations in glioblastoma, the underlying biological mechanisms remain poorly understood. 22309944 2012
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 Biomarker disease BEFREE In this study, we compared the two groups of survival outliers of glioblastoma with IDH wild-type, consisting of the glioblastoma patients who lived longer than 3 years (n = 17) and the patients who lived less than 1 year (n = 12) in terms of genome-wide DNA methylation profile. 31159876 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. 26061751 2015
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 GeneticVariation disease BEFREE Mutations in IDH genes are observed in over 70% of low-grade gliomas and some cases of glioblastoma. 26485760 2015